Isis Maria Quezado Soares Magalhães (Isis Magalhães, Isis Quezado Magalhães)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Peritoneal Dialysis

Respiratory Syndrome Coronavirus

Mesenchymal Stem Cells

Ejection Fraction

Top Venues

Cancer reports (Hoboken, N.J.)

This page only lists publications with an associated author ORCID identifier.

Publications

Klerize Anecely de Souza Silva, Isis Maria Quezado Soares Magalhães, Daniela Elaine Roth Benincasa, Daiane Keller Cecconello, Mariana Bohns Michalowski
Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature. Cancer reports (Hoboken, N.J.) 7 (8) (2024)
Klerize Anecely de Souza Silva, Isis Maria Quezado Soares Magalhães, Daniela Elaine Roth Benincasa, Daiane Keller Cecconello, Mariana Bohns Michalowski
Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature. Cancer reports (Hoboken, N.J.) 7 (8) (2024)
Klerize Anecely de Souza Silva, Isis Maria Quezado Soares Magalhães, Daniela Elaine Roth Benincasa, Daiane Keller Cecconello, Mariana Bohns Michalowski
Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature. Cancer reports (Hoboken, N.J.) 7 (8) (2024)
Claudia de Melo Oliveira, Victor Jablonski Soares, Josefina Aparecida Pellegrini Braga, Thaís Alcantara Bonilha, Isis Maria Quezado Soares Magalhães, Sandra Regina Loggetto, Ciliana Rechenmacher, Liane Esteves Daudt, Mariana Bohns Michalowski
The impact of COVID-19 in children with Sickle Cell Disease: Results of a multicentric registry. PloS one 18 (4) (2023)
Ricardo Camargo, Sushree S Sahoo, José Carlos Córdoba, Isis Maria Quezado Soares Magalhães
Germline GATA1 exon 2 mutation associated with chronic cytopenia and a non-down syndrome transient abnormal myelopoiesis with clonal trisomy 21. Leukemia 36 (9) (2022)